Drug intelligence / Profile preview

ADC2204

Development stage: Preclinical
Lead developer: Hangzhou Adcoris Biopharmaceuticals
Modality: Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
Administration: Intravenous

Overview

ADC2204 is a next-generation antibody-drug conjugate (ADC) that targets Nectin-4, a cell surface protein highly expressed in several solid tumors. It is being co-developed by Hangzhou Adcoris Biopharmacy and Lunan Pharmaceutical Group. Preclinical studies have shown that ADC2204 demonstrates superior safety, efficacy, and tolerability compared to the approved Nectin-4 targeting ADC enfortumab vedotin (PADCEV) in various cell-derived xenograft models. The drug is currently in preclinical development for the treatment of solid tumors.

Targets

PVRL4 (Nectin cell adhesion molecule 4)

Beyond the preview

Go deeper on ADC2204.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ADC2204.

Explore the full profile